Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 29c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($1.43), $0.29 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Femcare acquires UK harm reduction firm Orion for £3.6M
• Affirm Holdings (AFRM) PT Raised to $110 at Bernstein SocGen Group